Engineering Next-Generation LNPs for Precise Tissue Targeting, Repeat Dosing & Enhanced Clinical Performance

1:30 pm - Thursday 18th February 2027

  • Leveraging modular lipid architectures to tune biodistribution, pharmacokinetics, and immunogenicity across diverse therapeutic applications
  • Enabling cell- and organ-specific delivery through ligandfunctionalised LNP technologies to improve targeting precision and therapeutic index
  • Developing LNP platforms suitable for repeat administration while maintaining favourable safety and efficacy profiles in clinical settings
  • Demonstrating versatility across mRNA, saRNA, and other nucleic acid payloads to expand the therapeutic potential of LNP-enabled medicines

Speakers:

Chief Technology Officer
NeoVac